Literature DB >> 12947137

Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells.

M Hetzel1, D Walcher, M Grüb, H Bach, V Hombach, N Marx.   

Abstract

BACKGROUND: The release of matrix degrading enzymes such as matrix metalloproteinase 9 (MMP-9) from bronchial epithelial cells is critically involved in airway wall remodelling in chronic inflammatory processes of the respiratory system. MMP-9 expression is induced by inflammatory mediators such as tumour necrosis factor (TNF)-alpha, but to date nothing is known about the mechanisms of inhibition of MMP-9 expression in these cells.
METHODS: A study was undertaken to examine whether activators of the nuclear transcription factor peroxisome proliferator activated receptor gamma (PPARgamma) might modulate MMP-9 expression in two different bronchial epithelial cell lines.
RESULTS: PPARgamma was expressed and was functionally active in NL20 and BEAS cells. Activation of PPARgamma by rosiglitazone or pioglitazone significantly reduced TNF-alpha and PMA induced MMP-9 gelatinolytic activity in a concentration dependent manner in both cell lines, but did not alter the expression of tissue inhibitor of MMPs type 1 (TIMP-1), the local inhibitor of MMP-9. Northern blot analysis revealed a decrease in MMP-9 mRNA expression following treatment with PPARgamma which resulted from the inhibition of NF-kappaB activation in these cells, as determined by transient transfection assays and electromobility shift assays.
CONCLUSION: Activation of PPARgamma in human bronchial epithelial cells limits the expression of matrix degrading MMP-9. This might have therapeutic applications in chronic inflammatory processes of the respiratory system.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12947137      PMCID: PMC1746807          DOI: 10.1136/thorax.58.9.778

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  24 in total

Review 1.  Airway remodeling in asthma.

Authors:  J A Elias; Z Zhu; G Chupp; R J Homer
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

2.  Airway remodeling and repair.

Authors:  W Busse; J Elias; D Sheppard; S Banks-Schlegel
Journal:  Am J Respir Crit Care Med       Date:  1999-09       Impact factor: 21.405

3.  Immunohistochemical localisation of the matrix metalloproteinases MMP-3 and MMP-9 within the airways in asthma.

Authors:  B Dahlen; J Shute; P Howarth
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

4.  Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.

Authors:  J Sakamoto; H Kimura; S Moriyama; H Odaka; Y Momose; Y Sugiyama; H Sawada
Journal:  Biochem Biophys Res Commun       Date:  2000-11-30       Impact factor: 3.575

Review 5.  Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk?

Authors:  N Marx; P Libby; J Plutzky
Journal:  J Cardiovasc Risk       Date:  2001-08

6.  PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation.

Authors:  A Chawla; Y Barak; L Nagy; D Liao; P Tontonoz; R M Evans
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

Review 7.  Troglitazone: a review of its use in the management of type 2 diabetes mellitus.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

8.  Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells.

Authors:  N Marx; F Mach; A Sauty; J H Leung; M N Sarafi; R M Ransohoff; P Libby; J Plutzky; A D Luster
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

9.  Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis.

Authors:  Y Tsubouchi; H Sano; Y Kawahito; S Mukai; R Yamada; M Kohno; K Inoue; T Hla; M Kondo
Journal:  Biochem Biophys Res Commun       Date:  2000-04-13       Impact factor: 3.575

10.  Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling.

Authors:  L Benayoun; S Letuve; A Druilhe; J Boczkowski; M C Dombret; P Mechighel; J Megret; G Leseche; M Aubier; M Pretolani
Journal:  Am J Respir Crit Care Med       Date:  2001-10-15       Impact factor: 21.405

View more
  23 in total

1.  Human cytomegalovirus infection interferes with the maintenance and differentiation of trophoblast progenitor cells of the human placenta.

Authors:  Takako Tabata; Matthew Petitt; Martin Zydek; June Fang-Hoover; Nicholas Larocque; Mitsuru Tsuge; Matthew Gormley; Lawrence M Kauvar; Lenore Pereira
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

2.  Troglitazone-activated PPARγ inhibits LPS-induced lung alveolar type II epithelial cells injuries via TNF-α.

Authors:  Bo Xiao; Jing Xu; Guansong Wang; Peng Jiang; Fang Fang; Jian Huang; Jianchun Wang
Journal:  Mol Biol Rep       Date:  2010-12-14       Impact factor: 2.316

3.  mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease.

Authors:  S Soumian; R Gibbs; A Davies; C Albrecht
Journal:  J Clin Pathol       Date:  2005-12       Impact factor: 3.411

Review 4.  Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease.

Authors:  Maria G Belvisi; Jane A Mitchell
Journal:  Br J Pharmacol       Date:  2009-08-24       Impact factor: 8.739

5.  PPARs: Key Regulators of Airway Inflammation and Potential Therapeutic Targets in Asthma.

Authors:  Asoka Banno; Aravind T Reddy; Sowmya P Lakshmi; Raju C Reddy
Journal:  Nucl Receptor Res       Date:  2017-12-11

6.  PPARγ as a Potential Target to Treat Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases.

Authors:  Yongchun Shen; Lei Chen; Tao Wang; Fuqiang Wen
Journal:  PPAR Res       Date:  2012-06-17       Impact factor: 4.964

7.  Innate immunity and monocyte-macrophage activation in atherosclerosis.

Authors:  Joseph Shalhoub; Mika A Falck-Hansen; Alun H Davies; Claudia Monaco
Journal:  J Inflamm (Lond)       Date:  2011-04-28       Impact factor: 4.981

8.  Peroxisome proliferator-activated receptor-γ in induced sputum is correlated with MMP-9/TIMP-1 imbalance and formation of emphysema in COPD patients.

Authors:  Xiao-Ming Zhou; Gang Hou; Dong-Xue Gu; Qiu-Yue Wang; Li Zhao
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 9.  Peroxisome Proliferator-Activated Receptor-Gamma (PPAR-ɣ): Molecular Effects and Its Importance as a Novel Therapeutic Target for Cerebral Ischemic Injury.

Authors:  Ashi Mannan; Nikhil Garg; Thakur Gurjeet Singh; Harmeet Kaur Kang
Journal:  Neurochem Res       Date:  2021-07-20       Impact factor: 3.996

10.  PPARγ Ligands Regulate Noncontractile and Contractile Functions of Airway Smooth Muscle: Implications for Asthma Therapy.

Authors:  Chantal Donovan; Xiahui Tan; Jane Elizabeth Bourke
Journal:  PPAR Res       Date:  2012-08-16       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.